Pleiotropic effects of ARB in diabetes mellitus

Current Vascular Pharmacology

Volumn 9, Issue 2, 2011, Pages 136-144

  Saitoh, Shu ichi ^a   Takeishi, Yasuchika ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Metabolism; Nephropathy; Prevention; Retinopathy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INSULIN; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ALBUMINURIA; ARTERIOSCLEROSIS; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; DRUG WITHDRAWAL; EDEMA; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; KIDNEY FAILURE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLEIOTROPY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; BLOOD GLUCOSE; CARBOHYDRATE METABOLISM; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERTENSION;

EID: 79951709759     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016111794519363     Document Type: Review

References (43)

1. Mancia G, De Backer G, Dominiczak A, et al. Management of arterial hypertension of the european society of hypertension; european society of cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.
2. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004; 30: 487-96.
3. Mogensen C, Neldam S, Tikkanen I, et al. the CALM study group. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-4.
4. Toda N, Miyazaki M, Okamura T. Vascular neuroeffector function in two-kidney, one clip hypertensive dogs. J Hypertens 1985; 3: 503-9.
5. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
6. Grassi G, Seravalle G, Dell'Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study; CROSS Study. J Hypertens 2003; 21: 1761-9.
7. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463-73.
8. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the reninangiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
9. Fogari R, Derosa G, Zoppi A, et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 2005; 28: 209-14.
10. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-74.
11. Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
12. Verdecchia P, Schillaci G, Reboldi G, Borgioni C, Ciucci A, Porcellati C. Calcium antagonists and cardiovascular risk in patients with hypertension and type 2 diabetes mellitus: evidence from the PIUMA Study. Progetto Ipertensione Umbria Monitoraggio Ambulatoriale. Diabetes Nutr Metab 1999; 12: 292-9.
13. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. LIFE study group. Risk of new-onset diabetes in the Losartan Intervention for endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-86.
14. Zanchetti A, Elmfeldt D. Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Press 2006; 15: 71-9.
15. Pfeffer MA, Swedberg K, Granger CB, et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.
16. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004; 27: 247-55.
17. Braga MF, Leiter LA. Role of renin-angiotensin system blockade in patients with diabetes mellitus. Am J Cardiol 2009; 104: 835-9.
18. Califf RM, Boolell M, Haffner SM, et al. NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J 2008; 156: 623-32.
19. Kintscher U, Foryst-Ludwig A, Unger T. Inhibiting angiotensin type 1 receptors as a target for diabetes. Expert Opin Ther Targets 2008; 12: 1257-63.
20. Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 2007; 50: 467-73.
21. Mogensen CE. Urinary albumin excretion in diabetes. Lancet 1971; 2: 601-2.
22. Jackson CE, Solomon SD, Gerstein HC, et al.; CHARM Investigators and Committees. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009; 374: 543-50.
23. Fioretto P, Sutherland DE, Najafian B, Mauer M. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int 2006; 69: 907-12.
24. Vaag AA. Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study. Endocr Pract 2006; 12 (Suppl 1): 89-92.
25. Viberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-8.
26. Uzu T, Sawaguchi M, Maegawa H, Kashiwagi A. Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007; 30: 1581-3.
27. Makino H, Haneda M, Babazono T, et al.; INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30: 1577-8.
28. Bichu P, Nistala R, Khan A, Sowers JR, Whaley-Connell A. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manage 2009; 5: 129-40.
29. Sjølie AK, Klein R, Porta M, et al. DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo- controlled trial. Lancet 2008; 372: 1385-93
30. Chaturvedi N, Porta M, Klein R, et al.; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372: 1394-402.
31. Hammoud RA, Vaccari CS, Nagamia SH, Khan BV. Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature. Vasc Health Risk Manage 2007; 3: 937-45.
32. Persson F, Rossing P, Hovind P, et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scand J Clin Lab Invest 2008; 68: 731-8.
33. Iwai M, Chen R, Li Z, et al. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation 2005; 112: 1636-43.
34. Fukuda D, Sata M, Ishizaka N, Nagai R. Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 2008; 28: 90-6.
35. Stumpe KO, Agabiti-Rosei E, Zielinski T, et al.; MORE study investigators. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis 2007; 1: 97-106.
36. Fliser D, Buchholz K, Haller H. EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-7.
37. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16: 1135-40.
38. Imai E, Ito S, Haneda M, Chan JC, Makino H; ORIENT Investigators. Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design. Hypertens Res 2006; 29: 703-9.
39. Haller H, Viberti GC, Mimran A, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006; 24: 403-8.
40. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
41. Lewis EJ, Hunsicker LG, Clarke WR, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
42. Berl T, Hunsicker LG, Lewis JB, et al. Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003; 138: 542-9.
43. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-4.